Stathmin 1 expression predicts prognosis and benefits from adjuvant chemotherapy in patients with gallbladder carcinoma

Abstract

BackgroundAbnormal expression of Stathmin 1(STMN1) plays an important role in the proliferation and migration of gallbladder carcinoma (GBC). The purpose of current study is to investigate the prognostic significance of STMN1 in GBC patients after surgery.MethodsSTMN1 expression was evaluated with immunohistochemistry (IHC) on tissue microarrays from 70 GBC patients from a single institution between 2009 and 2013. The correlation between STMN1 expression and clinicopathological profiles and the prognosis was statistically inspected.ResultsHigh expression of STMN1 in tumoral tissue was associated with poor tumor differentiation (P<0.001), lymph node metastasis (P=0.028), advanced TNM stage (P=0.011) and short overall survival (P<0.001). Cox multivariate analysis identified the STMN1 expression as an independent prognostic factor. Integrating STMN1 expression with current TNM staging system generate a better clinical predictive model for GBC. Moreover, the postoperative adjuvant chemotherapy (ACT) showed significant benefit in TNM III- IV stage patients with low STMN1 expression.ConclusionSTMN1 might be an independent adverse prognostic factor in GBC patients after surgery, which could be combined with TNM staging system to improve the predictive accuracy for overall survival. Low expression of STMN1 stratified a subgroup of advanced GBC patients who could benefit from ACT.

Association of STMN1 with survival in solid tumors: A systematic review and meta-analysis

“…Taken together, our meta-analysis demonstrated that TMN1 could be used as a prognostic biomarker and a potential therapeutic target in solid tumors. 13,14,24-27,30,32-35,40,42, 12,13,16,[26][27][28]31,32,36,39,41,43,44 13 1.99 (1.51-2.61) < 0.05 86.1 < 0.05 Random effect NOS ⩾ 7 14,24,25,29,30,[33][34][35]37,38,40,42 Nevertheless, several limitations should be considered with much caution in this meta-analysis, when interpreting our synthesized result. First, the most important limitation was that there was significant heterogeneity, and our sensitivity and subgroup analysis failed to identify its sources.…”

“…We then reviewed the full text of the remaining records at length; ultimately, 25 studies were determined eligible for this meta-analysis. 12–14,16,24–44…”

“…8,9 Moreover, STMN1 has been reported to be upregulated in several types of cancer tissues and correlated with tumor aggressiveness. 10,11 Thus, an increasing number of recent studies focused on exploring the prognostic value of STMN1 cancer patients, and suggested that higher expression of STMN1 predicted worse survival in patients with several types of solid tumors, such as head and neck squamous cell carcinoma, 12 gallbladder carcinoma, 13 esophageal squamous cell cancer, 14 lung carcinoma, 15,16 breast cancer, 17 and endometrial cancer. 18 However, because most of the published studies were limited by the small number of cases, the conclusions regarding the prognostic value of STMN1 expression in solid tumors remain indecisive.…”

STMN1 promotes the proliferation and inhibits the apoptosis of acute myeloid leukemiacells by activating the PI3K/Akt pathway

“…We thus showed that STMN1 levels were adversely associated with the clinical prognosis of AML patients. STMN1 has been found to be a potential prognostic marker for patients with different types of tumors, including colon cancer (Zhang et al, 2016), gastric cancer (Bai et al, 2017), pancreatic ductal adenocarcinoma (Li et al, 2015), meningioma (Wang et al, 2017a), gallbladder carcinoma (Bo et al, 2017), osteosarcoma (Zhao et al, 2018), esophageal squamous cell carcinoma (Ni et al, 2017), (Hsieh et al, 2010) and non-small cell lung cancer (Nie et al, 2015;Wang et al, 2017b). Our data and previous reports indicated that STMN1 may not be only a prognostic marker for solid cancer but could also serve as a prognostic marker for patients with leukemia.…”